Exact Sciences Corporation (EXAS)
| Market Cap | 19.17B |
| Revenue (ttm) | 3.08B |
| Net Income (ttm) | -986.58M |
| Shares Out | 189.47M |
| EPS (ttm) | -5.26 |
| PE Ratio | n/a |
| Forward PE | 120.02 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,700,844 |
| Open | 101.35 |
| Previous Close | 101.29 |
| Day's Range | 101.17 - 101.40 |
| 52-Week Range | 38.81 - 101.87 |
| Beta | 1.47 |
| Analysts | Buy |
| Price Target | 76.38 (-24.53%) |
| Earnings Date | Nov 3, 2025 |
About EXAS
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Ri... [Read more]
Financial Performance
In 2024, Exact Sciences's revenue was $2.76 billion, an increase of 10.37% compared to the previous year's $2.50 billion. Losses were -$1.03 billion, 404.0% more than in 2023.
Financial StatementsAnalyst Summary
According to 20 analysts, the average rating for EXAS stock is "Buy." The 12-month stock price target is $76.38, which is a decrease of -24.53% from the latest price.
News
Exact Sciences Reinforces International Leadership in Breast Cancer with Strong Presence at 2025 San Antonio Breast Cancer Symposium
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, will present 10 abstracts across its Precision Oncology portfolio at t...
Exact Sciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Exact Sciences Corporation - EXAS
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Exact...
Why the Stock Price of This Cancer Screening Company Soared 17% Thursday
Shares of cancer screening test maker Exact Sciences Corp. (EXAS) surged Thursday after Abbott Laboratories (ABT) announced a deal to acquire the company for about $21 billion.
Exact Sciences Corporation (EXAS) M&A Call Transcript
Exact Sciences Corporation ( EXAS) M&A Call November 20, 2025 9:00 AM EST Company Participants Michael Comilla - Vice President of Investor Relations. Robert Ford - Chairman of the Board, President &...
Biggest Stock Movers Today, Nov. 20: PACS, BBWI, & More
Markets were broadly lower on Thursday, giving up early gains as excitement about Nvidia's latest financial results gave way to worries about the future. PACS Group and Exact Sciences led gainers on t...
Why Exact Sciences Rallied Over 50% This Week
Exact agreed to be bought out by Abbott Labs for $105 per share. The buyout is at a hefty premium to the share price at the start of the week, but still well below Exact's 2021 highs.
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Exact Sciences Corporation (Nasdaq – EXAS)
BALA CYNWYD, Pa., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Exact Sciences Corporation (“Exa...
Why Exact Sciences Stock Surged Today
Abbott made a takeover offer for Exact Sciences. The two companies want to team up to combat cancer.
Is it too late to buy Exact Sciences stock after Abbott's $21B deal?
Exact Sciences (NASDAQ: EXAS) rallied nearly 20% on November 20 after Abbott Laboratories (NYSE: ABT) announced a $21 billion all-cash deal to acquire the molecular diagnostics company.
Top Stock Movers Now: Walmart, Nvidia, Exact Sciences, Bath and Body Works, and More
Major U.S. equities indexes turned lower Thursday afternoon, reversing early gains as a rally powered by Nvidia's (NVDA) blockbuster earnings after the bell Wednesday faded. The Dow Jones Industrial A...
Abbott's $21 Billion Exact Sciences Buyout Reshapes Cancer Diagnostics
Abbott Laboratories (NYSE: ABT) agreed on Thursday to acquire cancer screening company Exact Sciences Corp (NASDAQ: EXAS) for $105 per common share, representing a total equity value of approximately ...
Why Abbott is paying $21 billion for Exact Sciences and its Cologuard cancer test
Abbott is getting into the cancer-testing game with its $21 billion acquisition of Cologuard test maker Exact Sciences.
Abbott to Acquire Exact Sciences for $21 Billion
Abbott agreed to acquire Exact Sciences for $105 a share, representing a total equity value of about $21 billion.
Exact Sciences Stock Soars. Abbott Is Buying It in Deal Valued at $21 Billion.
Abbott Laboratories agrees to buy the cancer screening company in a cash deal.
Abbott bolsters diagnostics portfolio with up to $23 billion buyout of Exact Sciences
Abbott said on Thursday it would buy cancer test maker Exact Sciences in an up to $23 billion deal, bolstering the medical device maker's diagnostics business.
Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments
Acquisition adds a new growth vertical to Abbott's already high single-digit growth profile, gaining leadership in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics...
Why Exact Sciences Stock Blasted Nearly 24% Higher Today
The cancer diagnostics specialist might, just might, be on the verge of selling itself. The apparent would-be buyer is a top name in the U.S. pharmaceutical industry.
Exact Sciences Stock Jumps on Reported Deal Interest From Abbott Laboratories
A report said the conglomerate Abbott Laboratories is close to a deal to acquire the company.
Abbott is weighing takeover of Exact Sciences, Bloomberg News reports
Medical device maker Abbott Laboratories is nearing a potential takeover of cancer test maker Exact Sciences Corp , Bloomberg News reported on Wednesday, citing people familiar with the matter.
Exact Sciences Corporation (EXAS) Presents at Jefferies London Healthcare Conference 2025 Transcript
Exact Sciences Corporation ( EXAS) Jefferies London Healthcare Conference 2025 November 18, 2025 7:30 AM EST Company Participants Kevin Conroy - Chairman of The Board & CEO Aaron Bloomer - Chief Fina...
Exact Sciences Corporation (EXAS) Presents at 7th Annual Healthcare Symposium Transcript
Exact Sciences Corporation ( EXAS) 7th Annual Healthcare Symposium November 14, 2025 8:50 AM EST Company Participants David Harding Conference Call Participants Kevin Dreyer - GAMCO Investors, Inc. C...
Exact Sciences Announces Expiration of the HSR Waiting Period for Exclusive License to Freenome's Blood-Based Colorectal Cancer Screening Tests
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the expiration of the waiting period under the Hart-Sc...
Exact Sciences Announces Breakthrough Results from Landmark Study Demonstrating Superior Early Detection of Liver Cancer with Blood-Based Surveillance Test
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced pivotal clinical validation results from the ALTUS stu...
Why Exact Sciences Stock Blasted Higher on Tuesday
The healthcare diagnostics specialist posted its latest set of quarterly figures. This featured a surprise net profit, among other goodies.
These Analysts Raise Their Forecasts On Exact Sciences Following Better-Than-Expected Q3 Results
Exact Sciences Corporation (NASDAQ:EXAS) reported better-than-expected third-quarter financial results and raised its FY25 sales guidance above estimates on Monday.